bisantrene has been researched along with panobinostat in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, BS; Murray, D; Nieto, Y; Popat, U; Valdez, BC; Yuan, B | 1 |
1 other study(ies) available for bisantrene and panobinostat
| Article | Year |
|---|---|
Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells.
Topics: Anthracenes; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Decitabine; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Panobinostat; Phthalazines; Piperazines; Sulfonamides | 2022 |